Shilajit and Painkillers: Interactions with Ibuprofen, Diclofenac, Naproxen and Paracetamol
Leila WehrhahnUpdated:Key points at a glance:
Shilajit is often described in relation to antioxidant properties and modulation of inflammatory processes. There is no robust evidence for a protective interaction with ibuprofen, diclofenac, naproxen or paracetamol. Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with an increased risk of gastrointestinal bleeding and kidney-related side effects. Paracetamol may place a burden on the liver. Additional risks may arise from low-quality products that contain heavy metals. It is generally advised to use the lowest effective dose for the shortest possible duration. A time gap of 2 to 3 hours between intakes is often recommended. Any risks should be assessed with a healthcare professional.
Shilajit is a natural substance from high mountain regions, rich in minerals and humic substances, and is often associated with antioxidant and inflammation-modulating properties. Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, diclofenac and naproxen, as well as paracetamol (acetaminophen), are among the most commonly used painkillers. This article looks at potential interactions, possible risks for the stomach/intestines, liver and kidneys, and offers practical, safety-focused considerations.
You can find more background on shilajit in our articles on its effects, interactions and side effects.
Key concerns: NSAIDs can increase gastrointestinal and kidney-related risks, paracetamol can place strain on the liver. Shilajit may have antioxidant properties, but product quality and potential additional risks also need to be considered.
How might interactions arise? (Mechanisms)
1) NSAIDs (ibuprofen, diclofenac, naproxen): stomach/intestines and kidneys
NSAIDs inhibit cyclo-oxygenases (COX) and thereby reduce prostaglandins, which help protect the gastric mucosa and support kidney blood flow. As a result, the likelihood of gastrointestinal ulcers/bleeding and – particularly in people with relevant risk factors – acute kidney injury can increase. The risk depends on dose and duration of use and varies between individual NSAIDs. At usual over-the-counter doses, ibuprofen is generally regarded as comparatively gastrointestinally well tolerated, naproxen lies in the middle range, and diclofenac is associated with a moderate risk. Overall, GI risk tends to be lower with the lowest effective dose used for the shortest possible time. (1)
Shilajit contains, among other components, fulvic and humic acids and has shown antioxidant and inflammation-modulating effects in preclinical and limited clinical data. In theory, this could help to dampen oxidative stress in the gastric mucosa; however, reliable clinical evidence for gastrointestinal protection when combined with NSAIDs is not available. (5)
2) Paracetamol: liver
Paracetamol is mainly metabolised in the liver; a small proportion is biotransformed via CYP2E1 to NAPQI, a reactive metabolite which can become hepatotoxic when glutathione stores are depleted. Overdoses are a leading cause of acute drug-induced liver failure; even therapeutic doses can occasionally be associated with transient increases in liver enzymes. (4) The antioxidant properties associated with shilajit do not reliably alter these fundamental mechanisms; a “protective” co-administration has not been demonstrated. Conversely, any additional substance processed by the liver – particularly at high doses or of poor quality – may contribute to the overall load on this organ. (4)
3) Renal and cardiovascular aspects with NSAIDs
NSAIDs can reduce glomerular filtration through prostaglandin inhibition, which, in situations such as dehydration, older age, existing chronic kidney disease or concomitant use of ACE inhibitors/ARBs/diuretics (“triple whammy”), may increase the risk of acute kidney injury. (3) Shilajit itself has not been clearly established as a direct amplifier of this risk; the main issues are existing NSAID-related risk factors and the quality of the shilajit product. (3,6)
4) Product quality and additional risks
A key topic is variation in product quality: reviews and market analyses indicate that some shilajit products may exceed guideline values for heavy metals. Such contaminants could place additional strain on the liver and kidneys – which may be particularly relevant in combination with potentially hepatotoxic paracetamol or kidney-sensitive NSAIDs. (6)
There is no robust evidence for protective effects of shilajit when used with NSAIDs or paracetamol. The main considerations are the established risks of NSAIDs and paracetamol, plus shilajit product quality.
Shilajit Capsules
What does the clinical evidence say?
At present there are no robust clinical data from direct interaction studies specifically examining “shilajit + common painkillers”. The evidence base includes:
- NSAIDs: Well-documented gastrointestinal risks (ulcerogenic potential, bleeding), which may be mitigated in some higher-risk individuals through the use of proton pump inhibitors (PPIs); differentiated GI and cardiovascular/renal risk profiles depending on substance and dose. (1,2,3)
- Paracetamol: Clear, dose-dependent hepatotoxic potential via NAPQI; increases in liver enzymes may also occur at therapeutic doses; N-acetylcysteine is used as an antidote in overdose situations. (4)
- Shilajit: Indications of antioxidant and anti-inflammatory properties, but only limited high-quality human studies; safety appears to be strongly dependent on product and quality. (5,6)
Risk assessment: severity and likelihood
| Substance | Main organ-related concern | Interaction relevance with shilajit | Overall risk (indicative) |
|---|---|---|---|
| Ibuprofen (NSAID) | GI, kidney | No proven pharmacokinetic interaction; theoretically additive strain if shilajit quality is poor | Low–moderate (dose-/duration-dependent) (1,3) |
| Diclofenac (NSAID) | GI, kidney, CV | As above; careful benefit–risk assessment advised in higher-risk individuals | Moderate (1,3) |
| Naproxen (NSAID) | GI, kidney | As above; cardiovascular profile partly more favourable, GI risk dose-dependent | Moderate (1,3) |
| Paracetamol | Liver | No demonstrated protective effect from shilajit; additive liver strain from supplements/contaminants is possible | Moderate–high in cases of incorrect use/overdose (4,6) |
The greatest established risks relate to paracetamol and the liver, and NSAIDs and the stomach/kidneys. Shilajit may contribute to overall risk particularly where product quality is poor or there are pre-existing conditions.
🧪 Shilajit Compatibility Check
Find out if there are any known risk factors that could contraindicate taking Shilajit.
Question 1 of 8
Practical considerations for safer use
- Assess individual risk: Age over 65, previous ulcers/bleeding, H. pylori, anticoagulants/corticosteroids, kidney disease, dehydration, and alcohol use or liver disease may increase the likelihood of side effects with NSAIDs/paracetamol. (1,3,4)
- Limit dose and duration: Use the lowest effective NSAID dose for the shortest possible period; for paracetamol, do not exceed the maximum daily dose recommended on the UK product label, and consider lower limits in the presence of liver-related risk factors. (4)
- Allow time intervals: Leave a gap of 2–3 hours between taking shilajit and painkillers to help reduce potential competition for absorption. Evidence is limited, but such spacing is a pragmatic precaution.
- Consider gastric protection: In those with an NSAID risk profile, PPI co-prescription may be considered where a healthcare professional judges it appropriate. (2)
- Ensure product quality: Use shilajit only from sources that can provide up-to-date testing (e.g. for heavy metals and microbiology). Look for standardised content and transparent quality documentation. (6)
- Monitoring: If shilajit and painkillers are to be used together repeatedly for more than 1–2 weeks, your doctor may consider checking baseline and follow-up liver values (ALT/AST) where paracetamol is used, and creatinine/eGFR where there is an NSAID-related kidney risk. If warning signs occur (severe upper abdominal pain, black/tarry stools, yellowing of the skin or eyes, dark urine, reduced urine output), seek medical assessment promptly. (1,3,4)
- Explore alternatives: If you are taking shilajit and experiencing recurrent pain, non-pharmacological measures (cold/heat, physiotherapy), topical NSAID gels for musculoskeletal issues, or short courses of low-dose paracetamol may be considered, always in consultation with a healthcare professional.
- Avoid alcohol: Do not consume alcohol with paracetamol and be cautious with alcohol when taking NSAIDs, to help limit liver- and GI-related risks. (4)
- Avoid “triple whammy” combinations: NSAID + ACE inhibitor/ARB + diuretic can increase the risk of acute kidney injury; particular care is needed in such situations. (3)
You can read more about potential shilajit interactions here: Shilajit interactions.
Conclusion
Current evidence does not indicate a clearly established pharmacological interaction between shilajit and commonly used painkillers, but it does highlight distinct, well-characterised risk profiles for these analgesics (GI/kidney aspects with NSAIDs; liver-related aspects with paracetamol). In practice, key levers for risk reduction include: low doses, short duration of use, timing the intake apart, consistent selection of high-quality shilajit products and, where there is frequent or concurrent use, clinical monitoring where appropriate. If you have individual risk factors, the combination should be discussed with a doctor in advance. Additional background can be found in our articles on shilajit effects and side effects.
Medical disclaimer
Important notice: This information does not replace professional medical advice. Always consult your doctor or pharmacist before taking shilajit together with any medicine. Each individual may react differently to food supplements and medicines.